President Donald Trump's April 2026 proclamation created a new tariff system for certain patented medicines and their active ingredients entering the United States. Its headline rate is 100%, but the policy is not a single duty applied to every imported drug.
Country agreements, company-specific onshoring arrangements and product exemptions all change the applicable rate. The first listed companies are scheduled to enter the system on July 31, with a second group following on September 29. That structure matters because a universal 100% description overstates the policy before customs collection has even begun.
The 100% Rate Is a Ceiling, Not a Universal Rate
The proclamation applies a 100% tariff to patented pharmaceutical products and patented active pharmaceutical ingredients identified in its first annex. It also says that when more than one rate could apply, the lowest applicable rate governs.
That instruction immediately narrows the headline. A qualifying company with an approved plan to expand US production receives a 20% rate instead. That lower rate is scheduled to rise to 100% on April 2, 2030, unless the policy changes before then.
The proclamation also allows the commerce secretary to increase a company's rate after determining that it has failed to meet its commitments. This makes company status an administrative decision tied to an agreement, not a permanent label that can be inferred from where a medicine was originally developed or manufactured.
Country and Company Deals Change the Duty
Imports from the European Union, Japan, South Korea, Switzerland and Liechtenstein are capped at 15% under the proclamation. Imports from the United Kingdom receive a 10% rate, with the possibility of a future reduction to zero under a broader agreement.
A separate temporary route gives a zero rate through January 20, 2029, to eligible companies that combine an approved onshoring agreement with a most-favoured-nation pricing agreement. The proclamation defines the latter as an agreement to provide specified medicines to US patients at prices no higher than the lowest price offered in comparable developed countries, subject to its terms.
These pathways mean the customs treatment depends on the product, country of origin, company and any approved agreement. A medicine made by one company can therefore face a different rate from a similar medicine made by another. The annexes and subsequent government determinations, rather than the 100% headline alone, identify the actual exposure.
Generics and Named Specialty Products Are Outside This Action
The proclamation says generic drugs and biosimilars are not subject to these tariffs at this time. It orders the commerce secretary and the US trade representative to review those products within a year and recommend whether further action is warranted. That review is a future decision, not a tariff enacted by this proclamation.
Several named specialty categories can receive a zero rate when imported from a country with a pharmaceutical trade framework or when the commerce secretary finds an urgent US need. The list includes certain orphan drugs, nuclear medicines, plasma-derived therapies, fertility medicines, cell and gene therapies, antibody-drug conjugates and medical countermeasures.
Those exclusions should not be converted into a claim that every product in a broad therapeutic area is automatically exempt. Eligibility depends on the definitions and conditions in the proclamation and annexes. Product-level classification is therefore essential to any estimate of the policy's reach.
The First Effective Date Is July 31
The first company list in Annex III is scheduled to become subject to the tariff at 12:01 a.m. Eastern time on July 31, 2026. The remaining listed companies follow on September 29. The Federal Register published procedures for companies seeking an onshoring agreement, including information on planned US investment, production capacity, timelines and pricing commitments.
The annexes list products and companies, while customs implementation determines which entries are charged and at what rate. A declared rate is not the same as revenue already collected, supply already shifted or prices already changed.
The administration presents the policy as a national-security measure intended to reduce reliance on foreign pharmaceutical production. Whether it produces that result will depend on completed facilities, regulatory approvals, manufacturing quality, capacity and the durability of company commitments. The proclamation does not itself measure any of those outcomes.
Patient Effects Must Be Measured, Not Predicted
The policy creates possible cost and supply pressures, but it does not establish that a particular patient will pay more or lose access to a medicine. Those outcomes depend on product-specific rates, inventories, contracts, insurance design, manufacturer decisions and whether domestic capacity becomes available.
The evidence needed after implementation is concrete: customs volumes and duties by product, approved company agreements, exemption decisions, changes in wholesale acquisition costs, shortage reports and the opening dates and output of US facilities. Without those data, both a promise of painless reshoring and a forecast of immediate medicine scarcity go beyond what the policy documents prove.
The hard test begins when the tariff starts, not when its headline is announced. A 100% ceiling may be politically striking, but the operative system is a matrix of lower rates, zero-rate pathways, dates and conditions. Public accountability requires the government to show which medicines actually paid which rate and whether the promised domestic capacity arrived before patients are asked to absorb the consequences.